MX2020000816A - Tratamiento de lesiones no inflamatorias. - Google Patents

Tratamiento de lesiones no inflamatorias.

Info

Publication number
MX2020000816A
MX2020000816A MX2020000816A MX2020000816A MX2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A
Authority
MX
Mexico
Prior art keywords
methyl
inflammatory lesions
mono
naphthacene
tetrahydroxy
Prior art date
Application number
MX2020000816A
Other languages
English (en)
Spanish (es)
Inventor
Alexandre Kaoukhov
David Berk
Vilma Sniukiene
Carsten Schmitz
Original Assignee
Almirall Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Llc filed Critical Almirall Llc
Publication of MX2020000816A publication Critical patent/MX2020000816A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020000816A 2017-07-21 2018-07-20 Tratamiento de lesiones no inflamatorias. MX2020000816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535572P 2017-07-21 2017-07-21
PCT/IB2018/000938 WO2019016609A1 (en) 2017-07-21 2018-07-20 TREATMENT OF NON-INFLAMMATORY LESIONS

Publications (1)

Publication Number Publication Date
MX2020000816A true MX2020000816A (es) 2020-08-17

Family

ID=63713912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000816A MX2020000816A (es) 2017-07-21 2018-07-20 Tratamiento de lesiones no inflamatorias.

Country Status (13)

Country Link
US (1) US20200222432A1 (enExample)
EP (1) EP3654988B1 (enExample)
JP (1) JP2020527607A (enExample)
KR (1) KR102662461B1 (enExample)
CN (1) CN111343991A (enExample)
AU (1) AU2018303807B2 (enExample)
BR (1) BR112020000968A2 (enExample)
CA (1) CA3070663A1 (enExample)
ES (1) ES2962380T3 (enExample)
IL (1) IL272124A (enExample)
MA (1) MA49641A (enExample)
MX (1) MX2020000816A (enExample)
WO (1) WO2019016609A1 (enExample)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (enExample) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
KR100926326B1 (ko) * 2001-04-05 2009-11-12 콜라제넥스 파마슈티칼스, 인크 여드름 치료 방법
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
PT2109602E (pt) 2006-12-21 2014-05-23 Paratek Pharm Innc Derivados de tetraciclina para o tratamento de infecções bacterianas, virais e parasitárias
SI2120963T1 (sl) * 2006-12-21 2019-02-28 Paratek Pharmaceuticals, Inc. Substituirane spojine tetraciklina za zdravljenje vnetnih kožnih motenj
WO2009141406A1 (en) * 2008-05-21 2009-11-26 Galderma Research & Development Maintenance therapy regimen for treating acne
BRPI0913326C1 (pt) * 2008-06-05 2021-05-25 Dow Pharmaceutical Sciences formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água
RU2012104572A (ru) * 2009-07-30 2013-09-10 Аллерган, Инк. Комбинация дапсона с адапаленом
US20140121188A1 (en) * 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
WO2012155146A1 (en) 2011-05-12 2012-11-15 Paratek Pharmaceuticals, Inc. Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
IL225240A0 (en) * 2012-03-15 2013-06-27 Meir Eini Use of tetracycline compounds for wound care and skin restoration
GB201615693D0 (en) * 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Also Published As

Publication number Publication date
JP2020527607A (ja) 2020-09-10
CA3070663A1 (en) 2019-01-24
AU2018303807A1 (en) 2020-02-13
EP3654988A1 (en) 2020-05-27
IL272124A (en) 2020-03-31
US20200222432A1 (en) 2020-07-16
AU2018303807B2 (en) 2023-08-24
CN111343991A (zh) 2020-06-26
ES2962380T3 (es) 2024-03-18
EP3654988B1 (en) 2023-09-06
WO2019016609A1 (en) 2019-01-24
KR20200031126A (ko) 2020-03-23
BR112020000968A2 (pt) 2020-07-14
KR102662461B1 (ko) 2024-04-30
MA49641A (fr) 2021-06-02

Similar Documents

Publication Publication Date Title
US11786496B2 (en) Composition and methods for treating intestinal hyperpermeability
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
CA2588296A1 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
MA35090B1 (fr) Polythérapie pour les malignités hématologiques
MX2012010161A (es) Metodo para tratar el mal de parkinson.
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
AU2014340303A1 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
IL273169B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
RU2018110580A (ru) Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2022003845A (es) Tratamientos cognitivos medicinales.
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MX2020000816A (es) Tratamiento de lesiones no inflamatorias.
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
MX2022012693A (es) Composicion que comprende metilfolato.
FI3864053T3 (fi) Rms:n hoito vaihtohoidolla
UY38340A (es) Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático
RU2013149634A (ru) Комбинации троспия и стимуляторов слюноотделения для лечения гиперактивного мочевого пузыря
RU2009107917A (ru) Аминоизохинолиновый ингибитор тромбина с улучшенной биодоступностью